NCT01363232View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

December 18, 2017

Conditions
Advanced Solid TumorsSelected Solid Tumors
Interventions
DRUG

BKM120 + MEK162

Trial Locations (12)

6500

Pfizer Investigative Site, Bellinzona

29605

Cancer Centers of the Carolinas CCC Faris, Greenville

45147

Pfizer Investigative Site, Essen

48201

Karmanos Cancer Institute Study Coordinator, Detroit

69120

Pfizer Investigative Site, Heidelberg

90033

Memorial Sloan Kettering Cancer Center MSKCC (2), New York

169610

Pfizer Investigative Site, Singapore

02115

Massachusetts General Hospital Mass General 2, Boston

77030-4009

University of Texas/MD Anderson Cancer Center MD Anderson PSC, Houston

M5G 2M9

Pfizer Investigative Site, Toronto

3584CX

Pfizer Investigative Site, Utrecht

08035

Pfizer Investigative Site, Barcelona

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT01363232 - Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | Biotech Hunter | Biotech Hunter